Entrada Therapeutics Inc
NASDAQ:TRDA
Entrada Therapeutics Inc
Cash from Investing Activities
Entrada Therapeutics Inc
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
Cash from Investing Activities
-$138.4m
|
CAGR 3-Years
-291%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-24%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$26.2B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-50%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$3.2B
|
CAGR 3-Years
-256%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-25%
|
See Also
What is Entrada Therapeutics Inc's Cash from Investing Activities?
Cash from Investing Activities
-138.4m
USD
Based on the financial report for Dec 31, 2023, Entrada Therapeutics Inc's Cash from Investing Activities amounts to -138.4m USD.
What is Entrada Therapeutics Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
-291%
Over the last year, the Cash from Investing Activities growth was 7%. The average annual Cash from Investing Activities growth rates for Entrada Therapeutics Inc have been -291% over the past three years .